Clinical Trial Update: Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency [Phase 2]

View source ↗

Summary

Phase 2 trial investigating carbamazepine for severe liver disease due to Alpha-1 antitrypsin deficiency was terminated; results posted later.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Liver Cirrhosis

Drugs mentioned

• Carbamazepine (Carbamazepine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Alpha-1-antitrypsin Deficiency, Liver Cirrhosis | Phase 2 | Status: TERMINATED | Results posted: 2021-10-12